FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP ABBV: AbbVie
2021-09-28 18:00:00
FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
ABBV34 trade ideas
ABBV buy nowPrices formed a falling wedge and breached its upper boundary at 107 to target 110.90
Stop losses closing below 106.38
Muted response to launch of $1.75bn partnership with RegenxbioFollowing 7% drop after FDA calls for arthritis drug to be labelled with heart-risk warning
ABBV will fly soon..False selling better to catch the falling knife from his handle I can anticipate this is the right handle to take it.
Happy trading.
ABBV Bounce/False BreakdownABBV got obliterated on some news, it broke down beneath its support level of 111 all the way down to 106, but got bought back up and closed above 111 holding the support level. This is looking like more boucne will happen tomorrow, with a long wicked candle showing false breakdown
Bad FDA news great time to addI still think Abbvie is undervalued great dividend growth play Added more today on the dip the 200ma Daily looks like strong support
Pull Back FishingBad news event )o: Price broke handle low of the large cup and handle pattern I drew a while back but never posted. The handle low was 110.
"FDA requires updated warnings on JAK inhibitors citing increased risks of heart events." ABBV is involved in the marketing of a JAK inhibitor which is for arthritis.
Good dividend payer with a yield at 4.31%. PE 9.5 EPS 12.64 Revenues appear to be rising quarterly.
I suppose you just never know what news will be released in the pharma/biotech world!
Price has fallen below the lower band with the SMA set on 80 exhibiting heavy selling pressure. The candle body is almost back inside the bands at this moment.
ABBV had made a yearly high and was closing in on the long term high, then BOOM!
Negative volume remains high showing institutional interest.
Ugly red candle today. I own this one and just makes me scratch my head and think WOW! I will buy more though.
No recommendation
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström’s macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
$ABBV - Calls above 120 & Puts below trend line$ABBV - Watch for calls above 120 & Puts below trend line, seeing some RSI divergence
$ABBV with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $ABBV after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 33%.
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
Bounce of the 21 weekly MA Love this company Q2 great numbers, the management team is strong adding some shares here.
ABBV LONG SWINGAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ABBV Rebound WaveABBV is forming a double top pattern and has posted shorter term lower highs, along with lower lows. I suspect this will trend down to the 110 area, that will act as the neckline to the double top
ABBVRising wedge into all-time highs. eh idk, maybe something like this depending on where it breaks out. Bear div on weekly price action and MACD.
ABBV Round upABBV is forming a rounding bottom pattern holding over the moving averages. It also has an upward trending support line of higher lows. I am looking for this to complete its rounding pattern to the 117.5 area.
AbbVie Bearish Butterfly AbbVie has been on my radar now for quite a bit. It’s one of the few Pharm. companies Warren Buffet holds and even know I’m not strong in the realm of Pharm. I have seen their marketing on TV increase quite a bit. Since I am away from my computer at the moment and posting from the TradingView App. I do not know their financials right off hand. I will update this idea with that information later. However, here we have a bearish butterfly. The pattern panned out super nicely. Once the pattern completed it made a little bit of a consolidation and dropped yesterday heavily. I will be looking at buying some AbbVie once it hits the 618 of the pattern structure… if the movement looks weak (not likely based off the strong sell off with high volume) I think the 618 is likely. All the other numbers that made up the PRZ were over projections of the traditional ABCD pattern (2.0) and a 1.618 over extension. So the massive sell off with high volume is not surprising… be looking out later today for the financial report this does not mean I am saying AbbVie is going to the ground but it is a nice little correction that we long term investors can take advantage.
$ABBV with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $ABBV after a Positive under reaction following its earnings release placing the stock in drift A
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
